Lecanemab for treatment of individuals with early Alzheimer’s Disease (AD) who are apolipoprotein E ε4 (ApoE ε4) non-carriers or heterozygotes

Background: Lecanemab, an antibody directed at Aβ-protofibrils and plaque, showed meaningful delay in disease progression and biological effects consistent with disease modification in the phase 3 Clarity AD trial. Objective: The objective of this paper is to present efficacy and safety results in A...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Richard Perry, Christopher Kipps, Maria Eugenia Soto Martín, Marco Bozzali, Giancarlo Logroscino, Sarah Trafford, Shobha Dhadda, Michio Kanekiyo, Amanda Goodwin, Mark Hodgkinson, Steven Hersch, Michael Irizarry, Lynn Kramer, Lutz Froelich
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Elsevier 2026-04-01
Saila:	The Journal of Prevention of Alzheimer's Disease
Gaiak:	Lecanemab Alzheimer’s disease Apolipoprotein E ε4 (ApoE ε4) non-carriers or heterozygotes
Sarrera elektronikoa:	http://www.sciencedirect.com/science/article/pii/S2274580726000312
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!